A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel DNA-based therapy, Elenagen, administered in combination with the standard chemotherapy gemcitabine in women with PROC and elevated CA-125…